Moderna (NASDAQ:MRNA) Price Target Cut to $27.00 by Analysts at Leerink Partners

Moderna (NASDAQ:MRNA) had its price objective decreased by stock analysts at Leerink Partners from $31.00 to $27.00 in a report issued on Thursday. The firm presently has an “underweight” rating on the stock. Leerink Partners’ price target suggests a potential downside of 20.73% from the company’s current price.

A number of other analysts have also recently weighed in on the company. Wolfe Research assumed coverage on Moderna in a research report on Friday, November 15th. They issued an “underperform” rating and a $40.00 price target for the company. Needham & Company LLC restated a “hold” rating on shares of Moderna in a report on Friday, November 8th. UBS Group lowered their price target on Moderna from $108.00 to $96.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Berenberg Bank boosted their price objective on shares of Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research note on Thursday. Finally, Jefferies Financial Group decreased their price objective on shares of Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a report on Tuesday, October 15th. Four equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Moderna has a consensus rating of “Hold” and an average price target of $75.58.

Moderna Trading Up 0.9 %

NASDAQ:MRNA opened at $34.06 on Thursday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The company has a market capitalization of $13.11 billion, a P/E ratio of -5.85 and a beta of 1.60. The stock’s 50 day moving average price is $40.85 and its 200 day moving average price is $66.75. Moderna has a 52 week low of $31.94 and a 52 week high of $170.47.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter last year, the firm earned ($1.39) EPS. Moderna’s revenue for the quarter was up 3.8% on a year-over-year basis. On average, research analysts forecast that Moderna will post -9.3 EPS for the current fiscal year.

Insider Transactions at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now owns 19,717 shares in the company, valued at approximately $843,690.43. This represents a 6.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last quarter, insiders have sold 2,664 shares of company stock valued at $115,210. 15.70% of the stock is owned by corporate insiders.

Institutional Trading of Moderna

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MRNA. MassMutual Private Wealth & Trust FSB lifted its stake in Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after purchasing an additional 389 shares during the period. Blue Trust Inc. lifted its position in shares of Moderna by 365.6% during the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after buying an additional 574 shares during the period. Larson Financial Group LLC lifted its position in shares of Moderna by 53.5% during the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after buying an additional 317 shares during the period. Rakuten Securities Inc. boosted its stake in Moderna by 477.3% in the 3rd quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock valued at $63,000 after buying an additional 778 shares in the last quarter. Finally, Itau Unibanco Holding S.A. bought a new stake in Moderna in the second quarter valued at $75,000. Institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.